Lilly victim of theft from Connecticut warehouse
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
Eli Lilly and Co.
Articles
Lilly buys right to underarm lotion for low sex drive
Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australia’s Acrux Ltd. to
an underarm testosterone lotion called Axiron for men with limited sex drive due to low levels of the hormone.
Lilly pays $50M-plus for rights to testosterone lotion
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
FDA says ‘not yet’ on Lilly’s once-weekly Byetta
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
Eli Lilly to buy European rights to Pfizer animal products
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Three Indiana companies among world’s most admired
Brightpoint, WellPoint and Cummins are recognized by Fortune magazine as being among the best in their industries.
Market surge doesn’t lift Lilly Endowment
Lilly Endowment’s resistance to diversify its holdings reached a new height last year, as it failed to sell a single share
of the underperforming Eli Lilly and Co. stock while the broader market surged.
Cornelius to retire as Bristol-Myers Squibb CEO
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Lilly, Transition Therapeutics make diabetes deal
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
To attack costs, Lilly accelerates R&D
With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep
getting higher for Eli Lilly and Co.’s efforts to develop drugs faster and cheaper.
Lilly to shift more employees to Covance
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
Perils of non-family managers
A former Toyota exec blasts non-family managers for the company’s problems. Are some Indianapolis-area companies better-
or worse-off after families relinquished control?
Obama health reform plan slaps drugmakers
Drugmakers, such as Indianapolis-based Eli Lilly and Co., would shoulder $3.3 billion in fees, face ban on pay-for-delay deals
with generic competitor.
Lilly, Merck, Pfizer starting research center
Three major U.S. drugmakers said they have formed a not-for-profit company in Asia to focus on cancer research and treatments.
WellPoint gets tax delay in Obama health plan
Insurers WellPoint Inc. and others would get a delay in taxes on premiums and high-cost medical benefits, along with additional
funding for expanding Medicaid, under a White House proposal
Teva gets European OK to sell generic of Lilly’s Evista
Evista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.
Lilly asks shareholders to lower takeover barrier
Eli Lilly and Co. directors have recommended that shareholders toss out the
drugmaker's most potent protection against unwanted takeovers: an 80-percent supermajority vote threshold for any shareholder
mutiny to succeed.
Lilly settles Arkansas Zyprexa suit for $18.5M
Arkansas Attorney General Dustin McDaniel on Tuesday announced an $18.5 million settlement of a lawsuit with Eli Lilly &
Co. over off-label marketing of the anti-psychotic drug Zyprexa.
Pfizer’s Viagra patent partially rejected in Lilly fight
The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn’t different
enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against
Eli Lilly and Co. over its rival Cialis drug.
Lilly awards pay increases to top executives
Eli Lilly and Co. CEO John Lechleiter’s total compensation increased $4.1 million in 2009.